By GINA KOLATA
Kymriah, approved recently by the F.D.A., with a $475,000 price tag, is first of a coming wave of treatments whose expected prices have alarmed economists, scientists and insurers.
Published: September 10, 2017 at 08:00PM
from NYT Health http://ift.tt/2jinaom
via IFTTT
from WordPress http://ift.tt/2xt1bB5
via IFTTT
No comments:
Post a Comment